ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,98
-0,68%
Dow Jones
40 211,72
0,53%
DAX
18 500,20
-0,54%
Brent Oil
83,77
-0,68%
Bitcoin
63 117,51
-2,67%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
21/04/201014h00Business WireAllos Therapeutics to Report First Quarter 2010 Financial Results on May 5, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
14/04/201023h07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/04/201022h34Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/04/201022h30Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/03/201022h20Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/03/201022h46Edgar (US Regulatory)Annual Report (10-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/03/201022h00Business WireAllos Therapeutics Reports Fourth Quarter and Full Year 2009 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/02/201015h01Business WireAllos Therapeutics to Participate in RBC Capital Markets Health Care ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/02/201014h00Business WireAllos Therapeutics to Report Fourth Quarter and Full Year 2009 Results on March 1, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/02/201023h35Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/02/201018h48Edgar (US Regulatory)Statement of Ownership (SC 13G)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/02/201019h25PR Newswire (US)MedNet Solutions Deploys Global Peripheral T-cell Lymphoma Registry for Allos TherapeuticsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/02/201014h00Business WireAllos Therapeutics to Present at BIO CEO & Investor ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/01/201014h00Business WireAllos Therapeutics to Present at J.P. Morgan Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/12/200912h25MarketwiredWall St Sense Offers In-depth Research on the Services, Financial and Healthcare Sectors' Key PlayersNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/12/200915h15Business WireAllos Therapeutics’ FOLOTYN™ Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Ly...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/12/200919h22Dow Jones News2nd UPDATE: Celgene To Buy Gloucester Pharma for At Least $340 MillionNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/12/200916h00Business WireAllos Therapeutics’ FOLOTYN™ Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Tre...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/12/200916h00Business WireAllos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN™ at 51st ASH Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/12/200914h00Business WireAllos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN™ (pralatrexate injection)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/12/200914h00Business WireAllos Therapeutics to Launch Global Registry for Patients with Peripheral T-Cell Lymphoma at the American Society of Hematolo...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/11/200914h00Business WireAllos Therapeutics Announces Issuance of U.S. Patent for FOLOTYNNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/11/200912h38MarketwiredRidgewater Equity Reviews the Following Equities Human Genome Sciences Inc., Intuit Inc., Advanced Battery Technologies, Linn EnNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/11/200914h00Business WireAllos Therapeutics Announces New Data on FOLOTYN™ to be Presented at the American Society of Hematology MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/11/200912h54MarketwiredAnalystChoice.com Provides Analytical Coverage on ELNK, NWSA, NTAP, ALTH, HANS and BPOPNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/11/200915h51Business WireAllos Therapeutics to Present at Upcoming Conferences in NovemberNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/11/200922h11Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/11/200922h01Business WireAllos Therapeutics Reports Third Quarter 2009 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/11/200911h12MarketwiredGlobal Market Perspective Review on ALTH, CINF, ALKS, DBRN, APOL and INFY from TheFortuneFinancial.comNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/10/200913h00Business WireAllos Therapeutics to Report Third Quarter 2009 Results on November 3, 2009NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

EU
VIV
Vivendi
NYSE
NKE
Nike
SPI
SP500
S&P 500
NYSE
DIS
Walt Disney
EU
AI
Air Liquide
EU
ORA
Orange
NYSE
JPM
JP Morgan Chase
NYSE
MRK
Merck
NASDAQ
NVDA
NVIDIA
EU
RNO
Renault
EU
CAP
Capgemini
NYSE
MCD
McDonalds
EU
EN
Bouygues
EU
LR
Legrand
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés